Close Menu

FDA

Core revenues were up 10 percent organically, while COVID-19 testing contributed $535 million to revenues in Q1 2021.

The researchers found that the reliable sampling of rare circulating tumor DNA fragments served as the key challenge for developing liquid biopsy assays.

This modular system uses a high-throughput version of the company's Applied Biosystems TaqPath COVID-19 Combo Kit, which received an EUA in March 2020.

The pilot program is intended to increase consistency and predictability when determining conformity with consensus standards and test methods.

Lucira Health's at-home molecular test received Emergency Use Authorization in November for prescription use.

The prescription-only test from Symbiotica is designed to detect immunoglobulin G against SARS-CoV-2 in dried blood spots obtained via fingerstick.

The test runs on DiaSorin's Liaison XL Analyzer and may be used by any lab CLIA-certified to perform moderate- or high-complexity tests, according to the FDA.

The DRP would be used to identify kidney cancer patients likely to benefit from dovitinib, a repurposed TKI for which Allarity plans to file an NDA this year.

The coalition includes partners from all over the world, including universities, research centers, and health systems in South Asia, Africa, South America, and the US.

Of the 31 companies in the index, 11 firms saw their stock prices increase, while 20 saw their share prices decline.

Pages